Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study)
Conditions: Congenital Rubella Infection; Measles Interventions: Biological: Measles-Rubella vaccine Bio Farma; Biological: MR Vaccine SII Sponsor: PT Bio Farma Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Indonesia Health | Measles | Measles Vaccine | Research | Rubella | Rubella Vaccine | Study | Vaccines